NICE recommends regular NHS funding for Roche’s lymphoma drug PolivyNICE has recommended regular NHS funding for Roche’s Polivy in certain lymphoma patients in final draft guidance, overturning Share XNICE recommends regular NHS funding for Roche’s lymphoma drug Polivyhttps://pharmaphorum.com/news/nice-recommends-regular-nhs-funding-for-roches-lymphoma-drug-polivy/
FDA to decide on TG Therapeutics’ lymphoma drug early next yearThe FDA has accepted TG Therapeutics’ filing for its lymphoma drug umbralisib, which if approved could compete against Share XFDA to decide on TG Therapeutics’ lymphoma drug early next yearhttps://pharmaphorum.com/news/fda-to-decide-on-tg-therapeutics-lymphoma-drug-early-next-year/
Incyte/Morphosys take on CAR-Ts with $198,000 per year antibodyIncyte and Morphosys’ Monjuvi antibody therapy has been approved for certain patients with lymphoma, as the companies hope Share XIncyte/Morphosys take on CAR-Ts with $198,000 per year antibodyhttps://pharmaphorum.com/news/incyte-morphosys-take-on-car-ts-as-lymphoma-antibody-monjuvi-approved-in-us/
Scopus Bio preps trials of gene-silencing immuno-oncology drugScopus BioPharma has licensed a gene-silencing drug from California’s City of Hope hospital that is due to start Share XScopus Bio preps trials of gene-silencing immuno-oncology drughttps://pharmaphorum.com/news/scopus-bio-preps-trials-of-gene-silencing-immuno-oncology-drug/
AbbVie forges $3.9 billion oncology alliance with GenmabAbbVie will pay Danish antibody specialist Genmab $750 million upfront for rights to a series of drugs headed Share XAbbVie forges $3.9 billion oncology alliance with Genmabhttps://pharmaphorum.com/news/abbvie-forges-3-9-billion-oncology-alliance-with-genmab/
NICE backs Celgene’s Revlimid for chemo-free lymphoma therapyNICE has backed Celgene’s Revlimid for routine NHS use in another indication, follicular lymphoma, as part of a Share XNICE backs Celgene’s Revlimid for chemo-free lymphoma therapyhttps://pharmaphorum.com/news/embargo-001-27-feb-nice-backs-celgenes-revlimid-for-chemo-free-lymphoma-therapy/
Epizyme eyes lucrative use for newly-launched TazverikUS biotech Epizyme is gearing up for a potentially lucrative second indication for its Tazverik (tazemetostat), after the Share XEpizyme eyes lucrative use for newly-launched Tazverikhttps://pharmaphorum.com/news/epizyme-eyes-lucrative-use-for-newly-launched-tazverik/
FDA to fast-track review of BMS’ CAR-T, ahead of shareholder deadlineSpeculators who bought into a risky three-drug bet are still on track for a payout following Celgene’s merger Share XFDA to fast-track review of BMS’ CAR-T, ahead of shareholder deadlinehttps://pharmaphorum.com/news/fda-to-fast-track-review-of-bms-car-t-ahead-of-shareholder-deadline/
MorphoSys gets $750m from Incyte for anti-CD19 cancer drugIncyte has agreed a deal with Germany’s MorphoSys to license an antibody that could be an alternative to Share XMorphoSys gets $750m from Incyte for anti-CD19 cancer drughttps://pharmaphorum.com/news/morphosys-gets-750m-from-incyte-for-anti-cd19-cancer-drug/
